CR

Claudio Rumazza

Venture Capital

Italy

Overview 

Claudio Rumazza is a seasoned professional in Venture Capital, currently serving as a Partner at Innogest SGR SpA and holding key positions in various companies like Bio4Dreams S.p.A. and MedLumics, S.L. His career highlights include being a part of the Investment Committee at LIFTT Spa and serving on the EIC Fund Advisory Committee at the European Innovation Council and SMEs Executive Agency (EISMEA).

Work Experience 

  • Investment Committee

    2020 - Current

  • Chairman Strategic Committee

    2020

    Bio4Dreams is a Life Sciences incubator and investment holding that offers tailor-made support programs together with expertise specific to Life Sciences and a multidisciplinary result-driven team, focused on providing structure and stability to the first steps of newly born startups

  • Partner

    2010 - 2020

    Innogest SGR is an indipendent Venture Capital firm with offices in Milan, Turin, San Francisco and Geneva investing in highly innovative and fast growing companies.

  • Board Director

    2017 - 2019

    Medlumics is developing a novel catheter for the treatment of atrial fibrillation through pulmonay vein ablation, using OCT (Optical Coherence Tomography) for a real-time, direct lesion assessment improving the efficacy of the treatment thanks to the creation of a more controlled continuous lesion.

  • Investor, Board Observer

    2016 - 2019

    Anaconda Biomed is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies based on a novel design combining the advantages of direct aspiration catheters and stent retrievers.

  • Investor, Board observer

    2015 - 2019

    Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis

  • Board Director

    2015 - 2019

    Newronika is a medical device company developing an adaptive deep brain stimulation device for movement disorders and a transcranial direct current stimulation system for depression, pain and neuro rehabilitation

  • Investor, Board observer

    2015 - 2019

    Angiodroid develops and markets the only automatic injector of carbon dioxide as a contrast medium in angiography.

  • Board Director

    2013 - 2019

    EryDel is specialized in the development of drugs and diagnostics delivered through patient's red blood cells by using a proprietary medical device technology. The first product based on Erydel's platform is EryDex, a treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive disorder with onset in the first years of life.

Articles About Claudio

Relevant Websites